DDInter1909 DDInter1676
Valbenazine is a modified metabolite of [tetrabenazine], and it is currently being approved for the treatment of various movement disorders, particularly tardive dyskinesia and chorea associated with Huntington's disease.[L47885,A261135] Tardive dyskinesia has long been regarded as a consequence of anti-dopamine receptor therapy, and until 2008 with the advent of [tetrabenazine], most treatments were ineffective. However, challenges in using [tetrabenazine] as a treatment of tardive dyskinesia included frequent dosing and safety and tolerability concerns. On April 2017, valbenazine was approved by the FDA under the brand name INGREZZA as the first and only approved treatment for adults with Tardive Dyskinesia (TD). On August 2023, valbenazine was again approved by the FDA for the treatment of chorea associated with Huntington's disease respectively. This approval was
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Valbenazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Valbenazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Binimetinib
Valbenazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Goserelin
Valbenazine {u} may lead to a major life threatening interaction when taken with {v} Enzalutamide
Valbenazine {u} may lead to a major life threatening interaction when taken with {v} Dacomitinib
Valbenazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Valbenazine may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Valbenazine may cause a moderate interaction that could exacerbate diseases when taken with Goserelin
Valbenazine may lead to a major life threatening interaction when taken with Enzalutamide
Valbenazine may lead to a major life threatening interaction when taken with Dacomitinib